Now a Stand-alone Firm, AB Sciex to Invest Further into R&D, Explore Acquisition Opportunities
February 05, 2010
Now a Stand-alone Firm, AB Sciex to Invest Further into R&D, Explore Acquisition Opportunities
With its sale to Danaher closed, AB Sciex will invest further into development of its mass specs and explore acquiring new technologies to strengthen its technology portfolio, company officials said on Tuesday.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PerkinElmer Drops Legal Actions Against MDS, Life Tech; FTC Gives Nod to Analytical Technologies Sale
January 29, 2010 / ProteoMonitor - FTC Asks MDS, Danaher for More Info; Anticipated Closing of Deals Pushed Back to Q1 2010
November 6, 2009 / ProteoMonitor - Thumbs Up All Around for Danaher Purchase of Life Tech, MDS' Mass Spec Business
September 10, 2009 / ProteoMonitor - Strong TripleTOF 5600 Sales Drive Mid-Teens Q2 Growth at AB Sciex
July 22, 2011 / ProteoMonitor - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor